HOE-140
HOE-140 Basic information
- Product Name:
- HOE-140
- Synonyms:
-
- HOE-140 (Icatibant)
- HOE140; ICATIBANT;HOE 140
- CS-1399
- Firazyr
- HOE 140 SYNTHETIC >99% SELECTIVE B2 BRAD YKIN
- d-arg-l-arg-l-pro-l-hyp-gly-l-(2-thienyl)ala-l-ser-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2α,3β,7aβ)-octahydro-1h-indole-2-carbonyl-l-arg
- Icatibant acetate, D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-octahydro-1H-indole-2-carbonyl-L-Arg
- HOE 140 Acetate
- CAS:
- 138614-30-9
- MF:
- C59H89N19O13S.C2H4O2
- MW:
- 1364.59
- EINECS:
- 206-141-6
- Mol File:
- 138614-30-9.mol
HOE-140 Chemical Properties
- storage temp.
- -20°C
- solubility
- DMSO:65.0(Max Conc. mg/mL);47.63(Max Conc. mM)
Ethanol:0.25(Max Conc. mg/mL);0.18(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);7.33(Max Conc. mM) - form
- A crystalline solid
- color
- White to off-white
HOE-140 Usage And Synthesis
Description
Although it is a rare disease, HAE is an autosomal dominant disorder that can be potentially life-threatening when swelling manifests itself within the upper airways. Antagonism of the constitutively expressed B2 receptor, therefore, would not only be beneficial in the treatment of HAE but also find application in inflammatory, allergic, and hyperalgesic disorders.Designed to possess enhanced metabolic stability with the inclusion of five non-proteinogenic amino acids, icatibant is a competitive and selective B2 receptor antagonist (devoid of activity against the inducible B1 receptor) with a Ki of 2.2±0.7 nM, and it is the first downstream targeting agent to receive regulatory approval. It joins purified C1 esterase inhibitor, danazol (an attenuated androgen), and tranexamic acid (an antifibrinolytic agent) as acute and prophylactic treatments for HAE.
Originator
Jerini (Germany)
Uses
Icatibant Acetate is a bradykinin B2 receptor antagonist that has been recently approved for treatment of acute attacks of hereditary angioedema (HAE).
Uses
Antagonist (bradykinin).
Definition
ChEBI: An acetate salt obtained by combining icatibant with acetic acid. Used for the treatment of acute attacks of hereditary angioedema in adult patients.
brand name
Metastat (CollaGenex);Firazyr.
Biochem/physiol Actions
B2 bradykinin receptors are present in the sensory neurons. Activation of B2 receptor by bradykinin is associated with pro-inflammatory, pain producing and cardiovascular responses. HOE-140 is a selective B2 bradykinin receptor antagonist. Presence of HOE-140 suppresses the effects of bradykinin and has been shown to have anti-hyperalgesic response, particularly towards inflammatory pain.
Synthesis
The peptidomimetic is prepared by standard solidphase technology on Wang resin employing Fmoc chemistry. Following trifluoroacetic acid cleavage with appropriate scavengers and HPLC purification, icatibant is ultimately isolated as its acetate salt.
HOE-140Supplier
- Tel
- 0571-88211921 15572296305
- sales4@gotopbio.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 400-6009262 16621234537
- chenyj@titansci.com
- Tel
- 021-50135380
- shchemsky@sina.com
HOE-140(138614-30-9)Related Product Information
- Exenatide acetate
- Octreotide acetate
- Isoamyl acetate
- Vinyl acetate
- Indole-3-acetic acid
- Ethylenediaminetetraacetic acid
- Atosiban
- Secretin Acetate
- Thymosin beta 4
- Gonadorelin acetate
- Calcitonin salmon
- HOE 140
- HOE-140
- H-GLY-PRO-ARG-OH ACETATE SALT
- H-LEU-ARG-OH
- 1-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-amine
- N-BENZYL-1-(1-PYRROLIDINYL)-2-PROPANAMINE